Linezolid should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the fetus. Studies show a possible increased risk of fetal toxicity, including bone marrow suppression. Close monitoring of the mother and fetus is necessary.
Because Linezolid is excreted in breast milk, the decision to use it while breastfeeding requires careful assessment. Weigh the benefits of treatment against the potential for adverse effects in the nursing infant. Infants should be monitored for adverse events, such as hematologic effects.
Before prescribing Linezolid to a pregnant or breastfeeding woman, discuss potential risks and benefits thoroughly with the patient. Consider alternative treatments if possible, particularly in early pregnancy. Regular monitoring of both maternal and infant blood counts is recommended during treatment and for a period afterward.
Consult relevant guidelines and expert advice for the most up-to-date recommendations. The information provided here should not replace professional medical judgment.
